Zoetis Inc. ZTS
We take great care to ensure that the data presented and summarized in this overview for Zoetis Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZTS
View all-
Vanguard Group Inc Valley Forge, PA41.2MShares$7.47 Billion0.14% of portfolio
-
Black Rock Inc. New York, NY36.8MShares$6.68 Billion0.15% of portfolio
-
State Street Corp Boston, MA19.7MShares$3.57 Billion0.15% of portfolio
-
State Farm Mutual Automobile Insurance CO Bloomington, IL16.2MShares$2.93 Billion2.53% of portfolio
-
Bank Of America Corp Charlotte, NC15.1MShares$2.74 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY15MShares$2.72 Billion0.93% of portfolio
-
Morgan Stanley New York, NY13.4MShares$2.43 Billion0.18% of portfolio
-
Geode Capital Management, LLC Boston, MA10.2MShares$1.86 Billion0.16% of portfolio
-
Wellington Management Group LLP Boston, MA9.44MShares$1.71 Billion0.3% of portfolio
-
Polen Capital Polen Capital Management LLC | Boca Raton, Fl7.05MShares$1.28 Billion3.06% of portfolio
Latest Institutional Activity in ZTS
Top Purchases
Top Sells
About ZTS
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Insider Transactions at ZTS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 03
2024
|
Michael B Mccallister Director |
SELL
Bona fide gift
|
Direct |
16,854
-99.99%
|
-
|
Jul 31
2024
|
Soria Ester Banque Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
307
-34.3%
|
$55,260
$180.04 P/Share
|
Jul 31
2024
|
Soria Ester Banque Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
895
+50.0%
|
-
|
Jun 30
2024
|
Wetteny Joseph Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,628
-33.16%
|
$2,357,644
$173.36 P/Share
|
Jun 30
2024
|
Wetteny Joseph Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,026
+38.94%
|
-
|
May 21
2024
|
Linda Rhodes Director |
SELL
Other acquisition or disposition
|
Direct |
541
-4.61%
|
$93,052
$172.79 P/Share
|
May 21
2024
|
Linda Rhodes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,441
+17.22%
|
-
|
Apr 18
2024
|
Roxanne Lagano Executive Vice President |
SELL
Open market or private sale
|
Direct |
923
-5.87%
|
$139,373
$151.17 P/Share
|
Mar 18
2024
|
Roxanne Lagano Executive Vice President |
SELL
Open market or private sale
|
Direct |
923
-5.54%
|
$159,679
$173.33 P/Share
|
Mar 11
2024
|
Willie M Reed Director |
SELL
Open market or private sale
|
Direct |
1,370
-12.06%
|
$249,340
$182.68 P/Share
|
Feb 21
2024
|
Gregory Norden Director |
SELL
Bona fide gift
|
Direct |
2,214
-100.0%
|
-
|
Feb 20
2024
|
Roxanne Lagano Executive Vice President |
SELL
Open market or private sale
|
Direct |
923
-5.25%
|
$172,601
$187.3 P/Share
|
Feb 20
2024
|
Kristin C Peck Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,000
-14.07%
|
$2,431,000
$187.2 P/Share
|
Feb 20
2024
|
Kristin C Peck Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+12.34%
|
$598,000
$46.09 P/Share
|
Feb 13
2024
|
Roxanne Lagano Executive Vice President |
SELL
Open market or private sale
|
Direct |
2,848
-13.95%
|
$529,728
$186.86 P/Share
|
Feb 12
2024
|
Roxanne Lagano Executive Vice President |
SELL
Open market or private sale
|
Direct |
363
-1.75%
|
$71,511
$197.74 P/Share
|
Feb 10
2024
|
Kristin C Peck Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,132
-10.84%
|
$3,572,004
$197.32 P/Share
|
Feb 10
2024
|
Kristin C Peck Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,813
+18.0%
|
-
|
Feb 10
2024
|
Rimma Driscoll Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
270
-2.79%
|
$53,190
$197.32 P/Share
|
Feb 10
2024
|
Rimma Driscoll Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
726
+6.98%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 138K shares |
---|
Other acquisition or disposition | 4.34K shares |
---|---|
Bona fide gift | 30.4K shares |
Payment of exercise price or tax liability | 41K shares |
Open market or private sale | 38.6K shares |